Söndag 10 Maj | 08:28:17 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-08-31 07:00 Kvartalsrapport 2026-Q2
2026-05-11 N/A X-dag ordinarie utdelning CRNA 0.00 NOK
2026-05-08 - Årsstämma
2026-04-15 - Bokslutskommuniké 2025
2026-01-12 - Extra Bolagsstämma 2026
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2025-06-05 - Årsstämma
2025-04-10 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-05-07 10:08:00

Oslo, 7 May 2026: Reference is made to Circio Holding ASA’s (OSE: CRNA) (the "Company") stock exchange announcement published on 6 May 2026, regarding the board of directors' resolution to increase the Company's share capital with NOK 70,516.20 by the issuance of 117,527 new shares, each with a nominal value of NOK 0.6, in order to issue new shares in the Company to facilitate an exercise of 65,500 share options and settlement of 52,027 restricted stock units (“RSUs“) pursuant to the Company's long-term incentive program for its employees and the Company's program for RSUs for the board members.

  • Primary insider, Damian Marron, chairman of the board of directors, has settled 14,012 RSUs under his RSU agreement and subscribed for 14,012 new shares in the Company following the exercise of RSUs. The subscription price for the RSUs was NOK 0.60 per new share.
  • Primary insider, Diane Mellett, member of the board of directors, has settled 2,020 RSUs under her RSU agreement and subscribed for 2,020 new shares in the Company following the exercise of RSUs. The subscription price for the RSUs was NOK 0.60 per new share.
  • Primary insider, Thomas Falck, member of the board of directors, has settled 10,376 RSUs under his RSU agreement and subscribed for 10,376 new shares in the Company following the exercise of RSUs. The subscription price for the RSUs was NOK 0.60 per new share. In order to cover tax obligations and payment of exercise price related to the settlement of RSUs, Thomas Falck has elected to sell 4,041 of his subscribed 10,376 shares.


No primary insiders exercised any share options.

Following the RSU settlement and subscription of new shares and the registration of the share capital increase pertaining to the new shares with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret), the above-mentioned primary insiders hold the following:

  • Damian Marron holds 311,863 shares and no RSUs
  • Diane Mellett holds 262,258 shares and 12,670 RSUs
  • Thomas Falck holds 415,535 shares (including shares held through Sølen AS) and no RSUs

Please see the attached notifications of trade for information regarding the settlement of RSUs and sales of new shares, for the purpose of covering tax obligations and paying exercise price, by the primary insiders.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.